Physician profile
Allison Doyle
NPI 1184309254
$1,490.39
in general payments reported to CMS, 2019-2025
22 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $26.33 · 2024: $1,051 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $256.42 | 2024-2025 | |
| Novo Nordisk INC | $206.76 | 2024-2025 | Rybelsus, Ozempic |
| Corcept Therapeutics | $166.17 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $136.29 | 2024 | |
| Lilly USA, LLC | $129.87 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $73.66 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.52 | 2024-2025 | Xifaxan |
| Pfizer INC. | $64.39 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $57.78 | 2024 | Airsupra, Breztri |
| Lundbeck LLC | $45.63 | 2024-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $33.20 | 2024 | |
| Janssen Pharmaceuticals, INC | $31.35 | 2024 | Xarelto |
| Neurocrine Biosciences, INC. | $29.34 | 2024 | Ingrezza |
| Brainscope Company, INC. | $26.33 | 2023 | Brainscope One |
| Alkermes, INC. | $25.09 | 2025 | Aristada, Lybalvi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $24.48 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $22.58 | 2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $22.19 | 2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.78 | 2024 | Jardiance |
| Dynavax Technologies Corporation | $18.44 | 2024 | Heplisav-B |
| Axsome Therapeutics, INC. | $15.33 | 2024 | Auvelity |
| Phathom Pharmaceuticals, INC. | $13.79 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.